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Abstract
Background: Current guidelines recommend electrical cardioversion (ECV) in patients with atrial fi-
brillation (AF) after at least 3 weeks of adequate non-vitamin K antagonist oral anticoagulant (NOAC) 
treatment without prior transesophageal echocardiography (TEE). However, in clinical practice in some 
centres, TEE is performed before ECV in patients with AF. The aim of the study was to evaluate preva-
lence of thromboembolic and hemorrhagic complications in patients with AF treated with NOACs and 
undergoing ECV without prior TEE.
Methods: This observational, multicentre study included consecutive patients with AF treated with 
NOACs who were admitted for ECV without prior TEE. Thromboembolic events and major bleeding 
complications were investigated during a 30-day follow-up.
Results: In the study group there were 611 patients, mean age was 66.3 ± 9.2 years, 40% were 
women. 52 (8.5%) patients had a low thromboembolic risk, 148 (24.2%) patients had an intermediate 
thromboembolic risk and 411 (67.2%) patients had a high thromboembolic risk.  In the study group 
253 (41.4%) patients were treated with rivaroxaban, 252 (41.2%) patients were treated with dabigatran 
and 106 (17.3%) patients were treated with apixaban. Reduced doses of NOACs were administered to 
113 (18.9%) patients. In the entire study group, there were no thromboembolic events or major bleeding 
complications during the in-hospital stay and the 30-day follow-up. 
Conclusions: In this “real-world” study of AF patients treated with NOACs, it was proved that ECV 
is safe without a preceding TEE, regardless of the risk of thromboembolic complications and of the type 
of NOAC used. (Cardiol J)
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Electrical cardioversion (ECV) is an integral 
part of the management of patients with atrial fibrilla-
tion (AF) who require a rhythm control strategy [1]. 
This procedure is available and s to perform, 
however, it requires an appropriate qualification 
of patients and their proper preparation. Although 
ECV is considered safe in general, it is associated 
with an increased risk of thromboembolic events. 
The risk of peri-cardioversion thromboembolic 
event is between 1.1% and 2% in patients not or 
insufficiently anticoagulated and between 0.28% 
and 0.8% in patients sufficiently anticoagulated 
[2–4]. According to the current AF guidelines, 
adequate oral anticoagulation is recommended 
for at least 3 weeks before and for a minimum of 
4 weeks after ECV in patients with AF > 48 hours 
or of unknown duration regardless of their stroke 
risk profiles. Both the European and the American 
Society of Cardiology state that transesophageal 
echocardiography (TEE) is not necessary in AF 
patients treated regularly with non-vitamin K 
antagonist oral anticoagulant (NOAC) for least 
3 weeks before cardioversion, but it is an alternative 
to pre-procedural anticoagulation [1, 5]. Secondary 
analyses from the landmark NOAC trials, as well as 
prospective randomized trials evaluating NOACs for 
cardioversion, have found NOACs safe in patients 
with AF undergoing cardioversion [6–12]. There 
are limited data on post cardioversion outcomes of 
patients treated with NOACs (especially in the group 
without TEE before ECV) in clinical practice outside 
clinical trials. The aim of the study was to evaluate 
prevalence of thromboembolic and hemorrhagic com-
plications in patients with AF treated with NOACs 
and undergoing ECV without prior TEE.
Methods
Study design and participants
This multicenter, observational study included 
patients with AF from three cardiology cent-
ers — an academic one, a military hospital and 
a regional hospital. The data were collected from 
January 2013 to December 2019. All consecutive 
adult patients with non-valvular AF treated with 
NOACs who underwent ECV were enrolled in the 
study. Exclusion criteria were TEE prior to ECV or 
moderate or severe mitral valve stenosis. 
In the presented study based on the results of 
the hospital registry, patients with AF treated with 
NOACs before ECV were evaluated. During the 
study period, 1321 patients with AF treated with 
NOACs before ECV were included. After applying 
the exclusion criteria described above, a total of 
611 patients were included in the study (Fig. 1). 
The study was approved by the ethics commit-
tees of each institution. The Bioethical Commis-
sion waived the requirement of obtaining patients’ 
informed consent.
Assessment data
Investigators collected retrospectively base-
line characteristics regarding demographics, medi-
cal history, type of AF, diagnostic test results and 
pharmacotherapy.
Thromboembolic risk was defined according to 
CHA2DS2-VASc (Congestive Heart Failure, Hyper-
tension, Age ≥ 75 years, Diabetes Mellitus, Stroke/ 
/Transient Ischemic Attack, Vascular Disease, Age 
65–74 years, Sex Category) score. 
Vascular disease was defined as angiographi-
cally significant coronary artery disease, previous 
myocardial infarction, peripheral arterial disease 
or aortic plaque. 
According to CHA2DS2-VASc score, low throm-
boembolic risk patients were classed as having 
a score of 0 (1 in women), intermediate thrombo-
embolic risk patients as having a score of 1 (2 in 
women), and high thromboembolic risk patients as 
having score ≥ 2 (≥ 3 in women). 
Patients were divided into three groups ac-
cording to the AF type (paroxysmal, persistent, 
and permanent AF) based on a careful and thorough 
Figure 1. Flow chart of the study; ECV — electrical car-
dioversion, NOAC — non-vitamin K antagonist oral an-
ticoagulant, TEE — transesophageal echocardiography.
Patients with atrial brillation
treated with NOAC undergoing ECV
N = 1321
Excluded patients treated 
with NOAC undergoing 
TEE before ECV
N = 710
Patients with atrial brillation treated
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analysis of all available medical documentation. 
AF was defined as permanent in patients whose 
ECVs were ineffective and another ECVs were 
not planned.
The estimated glomerular filtration rate 
(eGFR) was calculated using the Modification of 
Diet in Renal Disease Study equation. 
Management of anticoagulation therapy
All patients received NOACs (apixaban, dabi-
gatran, or rivaroxaban) for at least 3 weeks before 
ECV and all of them declared regular NOAC use. 
Echocardiographic evaluation
In all the centers, transthoracic echocardio-
graphy examinations were conducted prior to 
the scheduled ECV in most patients. All exams 
were performed by certified echocardiographers 
(second-degree accreditation in echocardiogra-
phy of the Section of Echocardiography of the 
Polish Cardiac Society [PCS]), using the General 
Electric Vivid 7 or E95 Ultrasound System (Gen-
eral Electric, Milwaukee, Wisconsin), the EPIQ 
7 Ultrasound Machine (Philips Medical Systems, 
Andover, Massachusetts, USA), or the iE33 Ultra-
sound Machine (Philips Medical Systems, Andover, 
Massachusetts, USA). The analysis included the 
left atrial anteroposterior diameter, the left ven-
tricular end-diastolic diameter, the left ventricular 
end-systolic diameter and the left ventricular ejec-
tion fraction (LVEF).
Study endpoints
The information about major bleeding and 
such thromboembolic events as stroke, transient 
ischemic attack, and systemic embolism was col-
lected at the hospital stay and during the 30-day 
follow-up. The data connected with endpoint oc-
currence were obtained during phone visits.  
Stroke was defined as a sudden onset of a new, 
focal neurological deficit in a location consistent 
with the territory of a major cerebral artery, con-
firmed by imaging techniques, with symptoms that 
persisted for at least 24 hours. 
Transient ischemic attack (TIA) was classified 
as a brief episode of a focal neurological deficit with 
symptoms lasting < 24 hours. 
Systemic embolism was defined as an ischemic 
episode with an acute vascular occlusion of the 
artery of an extremity or organ documented by 
imaging or surgery. 
Major bleeding events were defined accord-
ing to the criteria identified by The International 
Society of Thrombosis and Hemostasis which 
included fatal bleeding, symptomatic bleeding in 
the critical area or organ (such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraar-
ticular, pericardial, or intramuscular with com-
partment syndrome), and any bleeding causing 
a decrease in the haemoglobin level of 2 g/dL 
(1.24 mmol/L) or more, or leading to transfusion 
of two or more units of whole blood or packed red 
blood cells [13].
Statistical analysis
Continuous data were described by means, 
standard deviations, medians and interquartile 
range (IQR). Categorical data were summarized by 
frequencies and percentages. Group comparisons 
were performed using the c2 or the Fisher exact 
test for categorical variables, one-way analysis of 
variance for normally distributed variables or the 
Kruskal-Wallis test for continuous, non-normally 
distributed variables (normality of distribution was 
checked with the Shapiro-Wilk test).
A two-tailed p-value < 0.05 was considered 
statistically significant. All statistical analyses 




A total of 611 patients were included, with a mean 
age of 66.3 ± 9.2 years, 40% were women.
In the study group 508 (83.1%) patients had 
hypertension, 126 (20.6%) diabetes mellitus, 168 
(27.5%) heart failure and 172 (28.2%) vascular 
disease. Hypertension, impaired renal function 
and vascular disorders were the most common 
concomitant diseases in the study group. Previ-
ous stroke/TIA/peripheral thromboembolism were 
noted in 82 (13.4%) patients. Mean CHA2DS2VASc 
score was 2.7 ± 1.6. Baseline characteristics of the 
study population are summarized in Table 1.
In the study group 253 (41.4%) patients were 
treated with rivaroxaban, 252 (41.2%) patients 
were treated with dabigatran and 106 (17.4%) 
patients were treated with apixaban. The reduced 
dose of NOACs was administered to 113 (18.9%) 
patients.
Comparison between clinical  
characteristics of patients according  
to the thromboembolism risk
In the study group, 52 (8.5%) patients had 
a low thromboembolic risk, 148 (24.2%) patients 
had an intermediate thromboembolic risk and 411 
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(67.3%) patients had a high thromboembolic risk. 
Patients in the groups of low, intermediate and 
high risks of thromboembolic complications did not 
differ in terms of particular AF type prevalence. 
Impaired renal function most often occurred in 
patients with a high risk of thromboembolic com-
plications. Apixaban, dabigatran and rivaroxaban 
were used with a similar incidence in particular 
stroke risk groups of patients. Reduced NOAC 
doses were most frequently used in patients with 
a high risk of thromboembolic complications com-
pared with patients of intermediate and low risks 
of thromboembolic complications (Table 1).
Comparison between clinical  
characteristics of patients treated  
with individual NOACs
Patients treated with particular NOACs pre-
sented similar age, sex and cardiovascular risk 
factors. There were no significant differences in 
CHA2DS2-VASc score. Patients on apixaban com-
pared with patients on dabigatran or rivaroxaban 
had more often impaired renal function defined as 
eGFR < 60 mL/min/1.73 m2 and more often per-
sistent type of AF. The reduced dose of NOAC was 
used in 30 (28.3%) apixaban patients, 52 (20.6%) 
dabigatran patients, and 31 (12.3%) rivaroxaban 
patients (p = 0.0009). Table 2 shows characteristic 
details in patients treated with apixaban, dabigatran 
and rivaroxaban. 
Study endpoints
In the entire study group, there were no throm-
boembolic events or major bleeding complications 
during the in-hospital stay or the 30-day follow-up.
Discussion
The main finding of the present study was that 
in AF patients treated with NOACs, there were no 
thromboembolic events after ECV without prior 
TEE. The main clinical implication is that these 
findings show that the ECV in AF patients treated 
with NOACs can be safely performed without TEE 
in the routine clinical practice.
Electrical cardioversion is a commonly per-
formed procedure in patients with AF with nearly 
1 in 5 patients in ORBIT-AF II registry having an 
ECV during the study period [14]. In accordance 
with the international AF guidelines, TEE is a pre-
procedural examination recommended as an alter-
native to the adequate oral anticoagulation [1, 5]. 
Transesophageal echocardiography is a semi-
invasive procedure generally safer when conducted 
Table 1. Baseline characteristics of the study 
group. 




Mean ± SD 66.3 ± 9.2
Median (IQR) 66.0 (59.0–73.0)
< 65 275 (45%)
65–74 203 (33.2%)
≥ 75 133 (21.8%)
Female 245 (40.1%)
Clinical history
Heart failure 168 (27.5%)
Hypertension 508 (83.1%)
Diabetes mellitus 126 (20.6%)
Stroke, TIA, peripheral  
thromboembolic
82 (13.4%)
Vascular disease 172 (28.2%)
Bleeding 18 (2.9%)







Mean ± SD 2.7 ± 1.6
Median (IQR) 3 (2–4)
CHA2DS2-VASc = 0 (1 in female) 52 (8.5%)
CHA2DS2-VASc = 1 (2 in female) 148 (24.2%)
CHA2DS2-VASc ≥ 2 (≥ 3 in female) 411 (67.3%)
CHA2DS2-VASc ≥ 3 (≥ 4 in female) 320 (52.4%)
CHA2DS2-VASc ≥ 4 (≥ 5 in female) 188 (30.8%)
CHA2DS2-VASc ≥ 5 (≥ 6 in female) 88 (14.4%)
Echocardiography data
LVEF [%] N = 531
Mean ± SD 53.5 ± 8.0
Median (IQR) 55.0 (50.0–60.0)
LAd [mm] N = 530
Mean ± SD 40.3 ± 8.1
Median (IQR) 42.0 (36.0–45.0)
LVDd [mm] N = 532
Mean ± SD 51.9 ± 6.0
Median (IQR) 52.0 (48.0 - 56.0)
LVSd [mm] N = 401
Mean ± SD 35.3 ± 6.1
Median (IQR) 34.0 (31.0–38.0)
AF — atrial fibrillation; eGFR — estimated glomerular filtration rate; 
IQR — interquartile range; LAd — left atrial anteroposterior diam-
eter; LVDd — left ventricular end-diastolic diameter; LVEF — left 
ventricular ejection fraction; LVSd — left ventricular end-systolic 
diameter; NOAC — non-vitamin K antagonist oral anticoagulant; 
SD — standard deviation; TIA — transient ischemic attack
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by an experienced physician. Nevertheless, it is 
time-consuming, carries patient discomfort, not 
readily available at all times and it is associated, 
although rarely, with potentially life-threatening 
complications [15].
Thromboemboli after ECV are considered due 
to embolization of already existing thrombi present 
in the atrium (especially in the left atrial append-
age) at the time of ECV or due to the formation and 
subsequent embolization of de novo thrombi while 
the atrial function is still depressed in the first 
weeks after ECV [16, 17]. Therefore, performing 
TEE before EVC and ruling out thrombus in the 
left atrium does not guarantee that emboli will not 
be formed after ECV. 
The proportion of patients treated with 
NOACs, undergoing TEE prior to EVC is diversi-
fied in individual centers but high utilization of TEE 
before ECV these patients are still under observa-
tion to date, and may reflect a high accessibility to 
this imaging test but it is also a conservative ap-
proach to the safety of the procedure. TEE before 
ECV was performed in 41% of patients treated 
with rivaroxaban in X-VeRT study [18]. A post-hoc 
analysis of large studies has shown that 25% of pa-
tients treated with dabigatran (RE-LY) and 32% of 





= 0 (1 in female) 
N = 52
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= 1 (2 in female) 
N = 148
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Mean ± SD 66.3 ± 9.2 53.5 ± 4.2 58.1 ± 7.2 70.3 ± 2.8 < 0.0001
Median (IQR) 66.0 (59.0–73.0) 56.0 (49.8–61.0) 59.0 (55.0–62.0) 71.0 (65.5–76.0)
Bleeding 18 (2.9) 0 (0) 1 (0.7) 17 (4.1) 0.0535*
eGFR < 60 mL/min/1.73 m2 218 (35.6) 9 (17.3) 28 (18.9) 181 (44) < 0.0001
Type of AF 0.7761
Paroxysmal 96 (15.7%) 6 (11.5%) 21 (14.2%) 69 (16.8%)
Persistent 508 (83.1%) 46 (88.5%) 126 (85.1%) 336 (81.8%)
Permanent 7 (1.1%) 0 (0%) 1 (0.7%) 6 (1.5%)
Echocardiography data
LVEF [%] N = 531 N = 46 N = 126 N = 359 0.0015
Mean ± SD 53.5 ± 8.0 54.7 ± 7.9 55.5 ± 7.7 52.7 ± 8.0
Median (IQR) 55.0 (50.0–60.0) 55.0 (53.0–60.0) 57.5 (52.2–60.0) 55.0 (48.0–60.0)
LAd [mm] N = 530 N = 46 N = 126 N = 358 0.6731
Mean ± SD 40.3 ± 8.1 40.7 ± 7.9 40.4 ± 8.4 40.2 ± 8.1
Median (IQR) 42.0 (36.0–45.0) 42.5 (35.2–45.0) 42.0 (36.0–46.0) 41.0 (35.0–45.0)
LVDd [mm] N = 532 N = 46 N = 127 N = 359 0.0019
Mean ± SD 51.9 ± 6.0 50.0 ± 4.4 51.2 ± 6.1 52.4 ± 6.1
Median (IQR) 52.0 (48.0–56.0) 50.0 (47.0–52.8) 52.0 (49.0–55.0) 53.0 (48.0–56.0)
LVSd [mm] N = 401 N = 38 N = 97 N = 266 0.2749
Mean ± SD 35.3 ± 6.1 33.6 ± 3.6 35.4 ± 6.0 35.5 ± 6.4
Median (IQR) 34.0 (31.0–38.0) 34.0 (31.0–35.0) 35.0 (31.0–37.0) 34.0 (31.0–39.0)
Anticoagulation therapy 0.8682
Apixaban 106 (17.3%) 9 (17.3%) 23 (15.5%) 74 (18%)
Dabigatran 252 (41.2%) 17 (32.7%) 67 (45.3%) 168 (40.9%)
Rivaroxaban 253 (41.3%) 26 (50%) 58 (39.2%) 169 (41.1%)
Reduced dose of NOAC 113 (18.5%) 2 (3.8%) 9 (6.1%) 102 (24.8%) < 0.0001
*CHA2DS2-VASC = 0 excluded. Abbreviations — see Table 1 
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Mean ± SD 66.0 ± 10.0 66.2 ± 10.3 65.6 ± 10.4
Median (IQR) 67.0 (59.0–73.0) 65.5 (59.0–74.0) 67.0 (60.0–73.0)
Age < 65 years 48 (45.3%) 117 (30%) 110 (43.5%) 0.3707
Age 65–74 years 32 (30.2%) 76 (30%) 95 (37.5%)
Age ≥ 75 years 26 (24.5%) 59 (23.3%) 48 (19%)
Female 44 (41.5%) 97 (38.5%) 104 (41.1%) 0.7923
Clinical history
Heart failure 26 (24.5%) 80 (31.6%) 62 (24.5%) 0.1433
Hypertension 84 (79.2%) 215 (85%) 209 (82.6%) 0.3587
Diabetes mellitus 26 (24.5%) 44 (17.4%) 56 (22.1%) 0.2369
Stroke, TIA, peripheral thromboembolic 13 (12.3%) 35 (13.8%) 34 (13.4%) 0.9187
Vascular disease 19 (17.9%) 68 (26.9%) 85 (33.6%) 0.0093
Bleeding 7 (6.6%) 5 (2%) 6 (2.4%) 0.0751
eGFR < 60 mL/min/1.73 m2 45 (42.5%) 99 (39.1%) 74 (29.2%) 0.0174
Type of AF
Paroxysmal 6 (5.7%) 45 (17.8%) 45 (17.8%) 0.0104
Persistent 99 (91.5%) 205 (81%) 204 (81%)
Permanent 1 (1.5%) 2 (0.8%) 4 (1.6%)
Thromboembolic risk
CHA2DS2-VASc score 0.9772
Mean ± SD 2.7 ± 1.6 2.8 ± 1.7 2.7 ± 1.6
Median (IQR) 2.0 (2.0–3.8) 3.0 (1.0–4.0) 3.0 (2.0–4.0)
CHA2DS2-VASc = 0 9 (8.5%) 17 (6.7%) 26 (10.3%) 0.5562
(1 in female)
CHA2DS2-VASc = 1 23 (21.7%) 67 (26.5%) 58 (22.9%)
(2 in female)
CHA2DS2-VASc ≥ 2 74 (69.8%) 168 (66.4%) 169 (66.8%)
(≥ 3 in female)
Echocardiography data
LVEF [%] N = 99 N = 214 N = 218 0.3456
Mean ± SD 54.6 ± 7.0 53.4 ± 7.9 53.1 ± 8.5
Median (IQR) 56.0 (52.0–60.0) 55.0 (48.0–60.0) 55.0 (50.0–60.0)
LAd [mm] N = 96 N = 214 N = 220 0.0042
Mean ± SD 42.6 ± 8.3 39.5 ± 8.4 40.1 ± 7.7
Median (IQR) 43.8 (39.8–48.0) 41.0 (35.0–45.0) 41.0 (35.0–45.0)
LVDd [mm] N = 98 N = 215 N = 219 0.6350
Mean ± SD 52.0 ± 4.5 52.1 ± 6.6 51.7 ± 6.0
Median (IQR) 52.0 (48.2–55.0) 53.0 (48.5–56.0) 52.0 (48.0–55.0)
LVSd [mm] N = 94 N = 163 N = 144 0.4298
Mean ± SD 35.2 ± 4.4 35.5 ± 7.2 35.0 ± 5.9
Median (IQR) 35.0 (32.0–37.0) 34.0 (31.0–38.0) 34.0 (31.0–38.0)
Anticoagulation therapy
Reduced dose of NOAC 30 (28.3%) 52 (20.6%) 31 (12.3%) 0.0009
Abbreviations — see Table 1
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patients treated with apixaban (ARISTOTLE) had 
TEE performed before ECV [19, 20]. The Euro-
pean Heart Rhythm Association (EHRA) conducted 
a survey in 54 centers to examine contemporary 
clinical practice regarding pre-procedural diagnos-
tic work-up in AF patients. Only 12% of centres 
routinely performed TEE prior to the left atrial 
procedures, regardless of the type or duration of 
AF [21].
There is growing evidence that NOACs can 
safely be used for stroke prevention in AF patients 
undergoing ECV. In the presented study no throm-
boembolic events or major bleeding complications 
were noted during the first month after ECV. There 
are limited data on outcomes of patients treated 
with NOACs undergoing ECV without prior TEE. 
Many studies show prognosis in AF patients post 
ECV but part of them had TEE performed before 
ECV. Geurink et al. [14] showed that TEE was 
performed in 24% of NOAC treated patients and 
the incidence of stroke/TIA was low and was the 
same for patients with and without TEE. Frederik-
sen et al. [22] showed that in the group of patients 
treated with NOACs and undergoing ECV one of 
the patients had a thromboembolic complication 
within a 60-day observation.
In the presented study most of the patients 
had a high thromboembolic risk. Results of some 
studies suggest that in patients with a high risk 
of thromboembolic complications, the risk of left 
atrial appendage thrombus (LAAT) is high and in 
these patients TEE should be performed before 
cardioversion. In the group of 1148 patients treated 
with NOACs, CHA2DS2-VASc score ≥ 2 was an 
independent predictor of LAAT [23]. Barysiene 
et al. [24] showed that the risk of LAAT increases 
significantly in patients with CHA2DS2-VASc score 
≥ 5 points.  
Although in the presented study most patients 
were of high risk of thromboembolic complications, 
we did not observe a high proportion of patients 
with significantly reduced LVEF or patients with 
notably extended left atrium. Extension of left 
atrium and reduced LVEF are acknowledged fac-
tors increasing the prevalence of LAAT. Therefore, 
the study group of patients who did not have TEE 
before ECV did not include patients with signifi-
cant enlargement of left atrium or with reduced 
LVEF. Arguably, this fact influences the results of 
the study.
In the present study, what attracted atten-
tion was the high proportion of patients after past 
thromboembolic complications (13%). In the study 
of Friedriksen et al. [22] the proportion of patients 
treated with NOACs undergoing ECV after a past 
thromboembolic complication was 9.8% and in the 
study of Geurink et al. [14] — 6.8%. By extension, 
in the present study, the group of patients under-
going ECV without prior TEE was significantly 
burdened with concomitant diseases, which is also 
confirmed by a higher than in patients from cited 
examinations mean CHA2DS2-VASc score.
In the current examination, the lowest pro-
portion was constituted by patients treated with 
apixaban. Dabigatran was the first, rivaroxaban the 
second, and apixaban the third NOAC available in 
Poland, and all of them were available during the 
whole study period, thus probably apixaban patients 
were not a numerous group in the present study. 
Patients treated with individual NOACs did not 
differ in terms of thromboembolic complication 
risk, whereas apixaban patients were observed 
to have more frequent impaired renal function. 
Meta-analysis including 15 studies showed that 
the incidence of LAAT among different types of 
NOACs is similar [25]. 
The data from the present study remains in 
line with observational studies of other authors 
and are reassuring regarding the safety of NOACs 
for ECV in the routine clinical practice in patients 
without previous TEE as in the NOAC cardiover-
sion clinical trials. However, significant discrep-
ancies can still be observed in pre cardioversion 
procedures in individual centers. 
Strength and limitations
The current study has some strengths. First, 
the multicenter nature of this study can be repre-
sentative of the reality of the studied subgroup of 
patients in our region. What is more, the data were 
collected in three centers of different referential 
levels and in various regions of the country, which 
significantly influences the representative picture 
of the researched group of patients. 
On the other hand, the presented study has 
some limitations. The first one is the small size of 
the study group (especially of apixaban treated pa-
tients). Secondly, a limitation of study lies primarily 
in its partly retrospective nature. A retrospective 
analysis does not allow one to characterize the 
study cohort as precisely as with a prospective trial. 
This obviously limits the completeness of available 
data. In this case, there was no information about 
the reason for the reduced NOAC dose. Due to 
the unknown duration of AF it was not possible to 
differentiate between persistent and long-lasting 
persistent AF. Also, transthoracic echocardiogra-
phy was not performed in every patient in a real-life 
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setting and comprehensive data could not be col-
lected. In the examination of left atrium, left atrial 
volume index is a referential measurement. In the 
presented study, only left atrial anteroposterior 
diameter was available. Lastly, due to a lack of 
outcomes, the power of the study does not allow for 
a reasonable estimation of differences between the 
patients in particular thromboembolic risk groups 
and between particular NOAC groups. 
Conclusions
In this “real-world” study of AF patients 
treated with NOACs it was proved that ECV is 
safe without a preceding TEE regardless of the 
risk of thromboembolic complications and the 
treatment used.
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